Oncology: Breast Cancer Diagnostic and Treatment Devices

Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the markets for breast cancer diagnostic and therapeutic devices. Diagnostic device segments covered by this analysis include mammography, MRI, ultrasound, molecular breast imaging, PE mammography, tomographic optical breast imaging, RF imaging, and biopsy. Treatment devices covered by this analysis include lumpectomy, breast irradiation systems (eg EBRT, APBI, brachytherapy, IORT, and stereotactic radiotherapy), and minimally invasive ablation devices. 

The global market for breast cancer diagnostic and treatment devices is anticipated to see moderate, single-digit growth throughout the forecast period covered by this analysis (2017-22). Growth in unit sales is being driven by the increasing prevalence of breast cancer, increased accessibility to breast cancer imaging and diagnostic technologies, and availability of new breast-conserving treatment options. Global product sales are projected to expand at a compound annual growth rate (CAGR) of 6.2% during the 2017-22 forecast, increasing from approximately $4,417.3m in 2017 to an estimated $5,968.0m in 2022.